Effect of purified eicosapentaenoate ethyl ester on fibrinolytic capacity in patients with stable coronary artery disease and lower extremity ischaemia

Coronary Artery Disease

Volumn 7, Issue 11, 1996, Pages 837-842

  Tsuruta, Keiichirou ^a   Ogawa, Hisao ^a   Yasue, Hirofumi ^a   Sakamoto, Tomohiro ^a   Miyao, Yuji ^a   Tanae, Hidetsugu ^b   Kaiga, Kazuhiro ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Juzen Hospital   (Japan)

Author keywords

coronary artery disease; eicosapentaenoic acid; fibrinolytic capacity; lower extremity ischaemia

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID ETHYL ESTER; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HUMAN; LEG ISCHEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL;

EID: 0030461210     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199611000-00008     Document Type: Article

References (32)

1. Kannel WB, Skinner JJ Jr, Schwart MJ, Shurtleff D: Intermittent claudication: incidence in the Framingham study. Circulation 1970, 41:875-883.
2. Hertzer NR, Beven EG, Young JR, Ohara PJ, Ruschhaupt III WF, Graor RA, et al.: A classification of 1000 coronary arteriograms and results of surgical management. Ann Surg 1984, 199:223-233.
3. Hertzer NR: Recognition and management of associated coronary artery disease. In The Ischemic Leg. Edited by Kempczinski RF. Chicago: Year Book Medical Publishers; 1985:185-213.
4. Hamsen A, Wiman B, De Faire U, Blomback M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985, 313:1557-1563.
5. Almer L-O, Öhlin H: Elevated levels of the rapid inhibitor of plasminogen activator (t-PA) in acute myocardial infarction. Thromb Res 1987, 47:335-339.
6. Lucore CL, Sobel BE: Interactions of tissue type plasminogen activator with plasma inhibitors and their pharmacological implications. Circulation 1988, 77:660-669.
7. Masuda T, Yasue H, Ogawa H, Misumi I, Sakamoto T, Okubo H, et al.: Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina. Am Heart J 1992, 124:314-319.
8. Sakamoto T, Yasue H, Ogawa H, Misumi I, Masuda T: Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction. Am J Cardiol 1992, 70:271-276.
9. Zamarron C, Lijnen HR, Collen D: Kinetics of the activation of plasminogen by natural and recombinant tissue-plasminogen activator. J Biol Chem 259:2080-2083.
10. Wun TC, Capuano A: Inhibition and regulation of fibrinolysis in human plasma at the plasminogen activator level. Blood 1987, 69:1354-1362.
11. Sprengers ED, Kluft C: Plasminogen activator inhibitors. Blood 1987, 69:381-387.
12. Verheijen JH, Chang GTG, Kluft C: Evidence for the occurrence of a fast-acting inhibitor for the tissue-type plasminogen activator in human plasma. Thromb Haemost 1984, 51:392-395.
13. Mehta J, Lawson D, Saldeen T: Reduction in plasminogen activator inhibitor-1 (PAI-1) with omega-3 polyunsaturated fatty acid (PUFA) intake. Am Heart J 1988, 116:1201-1206.
14. Mehta J, Mehta P, Lawson D, Saldeen T: Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987, 9:263-268.
15. Crutchley DJ, McPhee GV, Terris MF, Canossa-Terris MA: Levels of three homeostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor. Arteriosclerosis 1989, 9:934-939.
16. Olofsson BO, Dahlén G, Nilsson TK: Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989, 10:77-82.
17. Stico-Rahm A, Wiman B, Hamsen A, Nielsson J: Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990, 10:1067-1073.
18. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, et al.: Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991, 11:1821-1829.
19. Tremoli E, Camera M, Maderna P, Sironi L, Prati L, Colli S, et al.: Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. Arterioscler Thromb 1993, 13:338-346.
20. Kugiyama K, Yasue H, Sakamoto T, Sugiyama S, Ohgushi M, Ogawa H, et al.: Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 1993, 73:335-343.
21. Harris WS: Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989, 30:785-807.
22. Nozaki S, Matsuzaka Y, Hirano K, Sakat N, Kubo M, Tarui S: Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia. Int J Vitam Nutr Res 1992, 62:256-260.
23. Mizuguchi K, Yano T, Ishibashi M, Msada A, Mizota M, Saito Y, et al.: Mechanism of the lipid-lowering effect of ethyl all-cis-5,8,11,14,17-icosapentaenoate. Eur J Pharmacol 1993, 231:121-127.
24. Eriksson E, Ránby M, Gyzander E, Risberg B: Determination of plasminogen activator inhibitor in plasma using tPA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res 1988, 312:932-936.
25. Amiral J, Plassart V, Grosley M, Mimilla F, Contant G, Guyader AM: Measurement of tPA and tPA-PAI complexes by ELISA, using monoclonal antibodies: clinical relevance. Thromb Res 1988, 8 (suppl):99-113.
26. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
27. Leaf A, Weber PC: Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988, 318:549-557.
28. Fridey KE, Childs MT, Tsunehara CH, Fujimoto WF, Bierman EL, Ensinck JW: Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acids supplementation in type 2 diabetes. Diabetes Care 1989, 12:276-280.
29. Vessby B, Boberg M: Dietary supplementation with n-3 fatty acids may impair the glucose homeostasis in patients with non-insulin dependent diabetes mellitus. J Intern Med 1990, 228:165-171.
30. Sigurdsson G, Nicoll A, Lewis B: Conversion of very low density lipoprotein to low density lipoprotein. J Clin Invest 1975, 56:1481-1490.
31. 2(+)-catalyzed-oxidative modification. Biochem Biophys Res Commun 1991, 175:61-67.
32. Saito I, Saito H, Tamura Y, Yoshida S: Eicosapentaenoic acid inhibits cholesteryl ester accumulation in rat peritoneal macrophages by decreasing the number of specific binding sites of acetyl LDL. Clin Biochem 1992, 25:351-355.